A Retrospective Study of the Antibiotic-Resistant Phenotypes and Genotypes of Helicobacter Pylori Strains in China
Zishao Zhong,Zhenyu Zhang,Jing Wang,Yunlian Hu,Yang Mi,Bangshun He,Yushu Zhang,Ximei Zhang,Xingzhou Xia,Huang,Yuexing Lai,Min Lin,Chengxia Su,Zhiyi Zhang,Zhengqi Wu,Linzhi Lu,Beiping Zhang,Suiping Huang,Cailing Zhong,Xiaoming Zeng,Yun Peng,Guangxia Chen,Haihan Zhang,Guangqing Zhou,Shiyu Liu,Changqing Yang,Lijuan Yan,Aojun Chen,Guiying Zhang,Ping Xu,Shukui Wang,Pengyuan Zheng,Shuchang Xu,Hengjun Gao
2021-01-01
American journal of cancer research
Abstract:Helicobacter pylori antibiotic resistance is a serious concern in China, where it severely influences treatment for H. pylori infection. To overcome this, it is essential to apply personalized therapies based on local or individual data on antibiotic-resistant phenotypes or genotypes. We conducted a large-scale multi-center study with a retrospective cross-sectional observational design to investigate the antibiotic-resistant phenotypes and genotypes of H. pylori in China. Strains were isolated from the gastric biopsy samples of H. pylori-infected patients from five different regions in China. The strains were tested for antibiotic-resistant phenotypes and genotypes, and the agreement between the two was assessed. In total, 4242 H. pylori strains were isolated and cultured, with an 84.43% success rate. The primary and secondary antibiotic resistance rates of H. pylori were 37.00% and 76.93% for clarithromycin, 34.21% and 61.58% for levofloxacin, 2.20% and 6.12% for amoxicillin, 1.61% and 3.11% for furazolidone, 1.18% and 3.31% for tetracycline, and 87.87% and 93.48% for metronidazole, respectively. The dual-resistance patterns for metronidazole/clarithromycin, metronidazole/levofloxacin, and clarithromycin/levofloxacin were 43.6%, 38.4%, and 26.1%, respectively. Clarithromycin- and levofloxacin-resistant H. pylori phenotypes and genotypes showed satisfactory agreement. Based on these findings, clarithromycin- and levofloxacin-resistant genotype testing could partially replace traditional antibiotic susceptibility testing in China. Continuous monitoring and personalized treatments based on individual and local H. pylori antibiotic-resistance data remain necessary.